VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
Public ClinicalTrials.gov record NCT03603808. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals
Study identification
- NCT ID
- NCT03603808
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Enrollment
- 44 participants
Conditions and interventions
Conditions
Interventions
- Electroporation Device
- HPV DNA Plasmids Therapeutic Vaccine VGX-3100 Biological
- Laboratory Biomarker Analysis Other
Device · Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 20, 2018
- Primary completion
- Dec 30, 2024
- Completion
- Jun 16, 2025
- Last update posted
- May 7, 2026
2018 – 2025
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Grady Health System | Atlanta | Georgia | 30303 | — |
| Anal Dysplasia Clinic MidWest | Chicago | Illinois | 60614 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Laser Surgery Care | New York | New York | 10011 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Wake Forest Baptist health Sciences | Winston-Salem | North Carolina | 27157 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03603808, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03603808 live on ClinicalTrials.gov.